Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site
作者:Bruce E. Maryanoff、John C. O'Neill、David F. McComsey、Stephen C. Yabut、Diane K. Luci、Alfonzo D. Jordan、John A. Masucci、William J. Jones、Marta C. Abad、Alan C. Gibbs、Ioanna Petrounia
DOI:10.1021/ml200070g
日期:2011.7.14
Attenuation of fructose metabolism by the inhibition of ketohexokinase (KHK; fructokinase) should reduce body weight, free fatty acids, and triglycerides, thereby offering a novel approach to treat diabetes and obesity in response to modern diets. We have identified potent, selective inhibitors of human hepatic KHK within a series of pyrimidinopyrimidines (1). For example, 8, 38, and 47 exhibited KHK IC50
通过抑制酮己糖激酶(KHK;果糖激酶)来减弱果糖代谢应该可以降低体重、游离脂肪酸和甘油三酯,从而提供一种新的方法来治疗糖尿病和肥胖症以应对现代饮食。我们已经在一系列嘧啶并嘧啶 ( 1 ) 中鉴定了人肝 KHK 的强效选择性抑制剂。例如,8,38,和47个显示出KHK IC 50个12,7和8纳米的值,分别与也显示了强的蜂窝KHK抑制(IC 50 <500纳米),其涉及它们的固有效力VS KHK及其穿透细胞的能力。3 , 8 KHK配合物的X射线共晶结构和47揭示了酶的腺苷 5'-三磷酸 (ATP) 结合口袋内的重要相互作用。